[go: up one dir, main page]

DK0981375T3 - Farmaceutiske præparater indeholdende plasmaprotein - Google Patents

Farmaceutiske præparater indeholdende plasmaprotein

Info

Publication number
DK0981375T3
DK0981375T3 DK98946629T DK98946629T DK0981375T3 DK 0981375 T3 DK0981375 T3 DK 0981375T3 DK 98946629 T DK98946629 T DK 98946629T DK 98946629 T DK98946629 T DK 98946629T DK 0981375 T3 DK0981375 T3 DK 0981375T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical preparations
plasma protein
preparations containing
containing plasma
protein
Prior art date
Application number
DK98946629T
Other languages
Danish (da)
English (en)
Inventor
Lajos Hegedues
Krisztina Krempels
Krisztina Paal
Gabor Petho
Original Assignee
Human Rt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Rt filed Critical Human Rt
Application granted granted Critical
Publication of DK0981375T3 publication Critical patent/DK0981375T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK98946629T 1997-09-18 1998-09-17 Farmaceutiske præparater indeholdende plasmaprotein DK0981375T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9701554A HUP9701554D0 (en) 1997-09-18 1997-09-18 Pharmaceutical composition containing plazma proteins
PCT/HU1998/000086 WO1999013914A1 (en) 1997-09-18 1998-09-17 Pharmaceutical compositions containing plasma protein

Publications (1)

Publication Number Publication Date
DK0981375T3 true DK0981375T3 (da) 2003-05-05

Family

ID=90014222

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98946629T DK0981375T3 (da) 1997-09-18 1998-09-17 Farmaceutiske præparater indeholdende plasmaprotein

Country Status (33)

Country Link
US (5) US6743826B1 (pt)
EP (1) EP0981375B1 (pt)
JP (1) JP2001508806A (pt)
KR (1) KR100587962B1 (pt)
CN (1) CN1189216C (pt)
AR (1) AR017120A1 (pt)
AT (1) ATE230611T1 (pt)
AU (1) AU734695B2 (pt)
BG (1) BG64749B1 (pt)
BR (1) BR9812469A (pt)
CA (1) CA2269923C (pt)
CZ (1) CZ301326B6 (pt)
DE (1) DE69810612T2 (pt)
DK (1) DK0981375T3 (pt)
EA (1) EA004700B1 (pt)
ES (1) ES2187062T3 (pt)
HR (1) HRP980499A2 (pt)
HU (1) HUP9701554D0 (pt)
IL (1) IL135055A (pt)
LT (1) LT4736B (pt)
LV (1) LV12493B (pt)
NO (1) NO325294B1 (pt)
NZ (1) NZ503302A (pt)
PL (1) PL193067B1 (pt)
PT (1) PT981375E (pt)
RO (1) RO118695B1 (pt)
RS (1) RS50102B (pt)
SI (1) SI20189B (pt)
SK (1) SK284683B6 (pt)
TR (1) TR200001545T2 (pt)
TW (1) TWI222365B (pt)
WO (1) WO1999013914A1 (pt)
ZA (1) ZA988585B (pt)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US20070092563A1 (en) * 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
WO2000047187A1 (en) * 1999-02-11 2000-08-17 Kinetana Inc. Serum albumin-based parenteral formulations of polyene macrolides
DE60023324T2 (de) 1999-09-16 2006-07-20 Novo Nordisk A/S Zusammensetzung zur in-vitro befruchtung
EP1274404A1 (en) * 2000-04-10 2003-01-15 Teva Pharmaceutical Industries Ltd. Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
WO2001076559A1 (en) * 2000-04-10 2001-10-18 Teva Pharmaceutical Industries Ltd. Method 0f administration of paclitaxel-plasma protein formulation
ES2529300T3 (es) 2000-04-12 2015-02-18 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
CA2445763A1 (en) * 2001-05-01 2002-11-07 Angiotech Pharmaceuticals Inc. Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
EA200500210A1 (ru) 2002-07-16 2005-06-30 Медексис С. А. Конъюгаты стероидов, их получение и их применение
GR1004274B (el) 2002-07-16 2003-06-23 Medexis ���� Συμπλοκα στεροειδων ορμονων με πρωτεινες: νεες ουσιες για την ειδικη ανιχνευση και καταστροφη καρκινικων κυτταρων προερχομενων απο στερεους ογκους και αιματολογικες κακοηθειες
AU2003262025A1 (en) * 2002-09-12 2004-04-30 Nihon Medi-Physics Co., Ltd. Preparation for controlling binging of drug to plasma protein
SI1585548T1 (sl) * 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US20050079546A1 (en) * 2003-05-01 2005-04-14 Dasa Lipovsek Serum albumin scaffold-based proteins and uses thereof
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
US20050277584A1 (en) * 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US8391959B2 (en) * 2004-09-29 2013-03-05 Tel Hashomer Medical Research Infrastructure And Services Ltd. Composition for improving efficiency of drug delivery
US20060198891A1 (en) 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
RU2283133C1 (ru) * 2005-06-03 2006-09-10 Общество С Ограниченной Ответственностью "Ферон" Лечебное средство
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
CN103120653B (zh) * 2007-04-04 2015-09-30 希格默伊德药业有限公司 一种口服药物组合物
US8951570B2 (en) 2007-04-26 2015-02-10 Sigmoid Pharma Limited Manufacture of multiple minicapsules
WO2009116557A1 (ja) * 2008-03-21 2009-09-24 富士フイルム株式会社 薬剤含有組成物
CN101658516B (zh) * 2008-08-26 2011-10-05 齐鲁制药有限公司 紫杉醇类药物组合物及其制备方法
ES2530049T3 (es) 2009-05-18 2015-02-26 Sigmoid Pharma Limited Composición que comprende gotas de aceite
JP5911799B2 (ja) 2009-08-12 2016-04-27 シグモイド・ファーマ・リミテッドSigmoid Pharma Limited ポリマーマトリックスおよび油相を含んで成る免疫調節組成物
WO2011038073A1 (en) 2009-09-23 2011-03-31 Formatech, Inc. Methods for the preparation of liposomes comprising docetaxel
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
CN102802617B (zh) * 2009-12-18 2016-05-11 埃克索多斯生命科学有限合伙公司 用于稳定的液体药物制剂的方法和组合物
EP2531173B1 (en) * 2010-02-03 2018-09-26 Oncbiomune, L.L.C. Taxane- and taxoid-protein compositions
AR093275A1 (es) 2010-03-17 2015-05-27 Centro De Excelencia En Productos Y Procesos De Cordoba (Ceprocor) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
ES2989832T3 (es) 2014-03-18 2024-11-27 Izun Pharmaceuticals Corp Composiciones de cannabinoides unidos a proteínas
CA2947067C (en) 2014-05-08 2023-02-14 Panoptes Pharma Ges.M.B.H. Compounds for treating ophthalmic diseases and disorders
SMT202100137T1 (it) 2014-11-07 2021-05-07 Sublimity Therapeutics Ltd Composizioni comprendenti la ciclosporina
AR100034A1 (es) 2015-01-30 2016-09-07 Consejo Nac De Investig Científicas Y Técnicas (Conicet) Una composición farmacéutica soluble en agua que comprende, al menos, una sustancia terapéuticamente activa y, al menos, una sustancia con capacidad para formar micelas
WO2016182929A1 (en) 2015-05-08 2016-11-17 Spectral Platforms, Inc. Albumin-based non-covalent complexes and methods of use thereof
CN107683134B (zh) 2015-05-15 2021-02-23 珠海贝海生物技术有限公司 多西他赛及人血清白蛋白复合物
EP3310338A4 (en) * 2015-06-18 2018-12-26 Matinas BioPharma Nanotechnologies, Inc. Compositions and methods for treating inflammatory disease or conditions
WO2017083397A1 (en) * 2015-11-09 2017-05-18 Cayo Max A Cardiac glycosides for the treatment of hypercholesterolemia
JP6931004B2 (ja) 2016-01-11 2021-09-01 エピセントアールエックス,インコーポレイテッド 2−ブロモ−1−(3,3−ジニトロアゼチジン−1−イル)エタノンの静脈内投与のための組成物および方法
CN113288862B (zh) * 2016-08-03 2023-06-02 珠海贝海生物技术有限公司 含阿瑞吡坦的组合物及其制备方法和应用
WO2018081520A1 (en) 2016-10-27 2018-05-03 Zhuhai Beihai Biotech Co., Ltd. Neutral ph compositions of docetaxel and human serum albumin
WO2018163187A1 (en) 2017-03-09 2018-09-13 Izun Pharmaceuticals Corp. Stabilized protein-bound cannabinoid compositions
EP3602065A4 (en) 2017-03-20 2020-12-23 Spectral Platforms, Inc. SPECTROSCOPY METHODS TO DETECT AND CHARACTERIZE MICRO-ORGANISMS
AU2018297348B2 (en) 2017-07-07 2024-07-25 Epicentrx, Inc. Compositions for parenteral administration of therapeutic agents
US11510901B2 (en) 2018-01-08 2022-11-29 Epicentrx, Inc. Methods and compositions utilizing RRx-001 combination therapy for radioprotection
WO2019170848A1 (en) * 2018-03-09 2019-09-12 Panoptes Pharma Ges.M.B.H. Ophthalmic formulation
EP3811982A1 (en) * 2019-10-25 2021-04-28 Université de Strasbourg Protein-based biomaterial with viscoelastic behaviour, process for obtaining it and uses thereof
ES3037830T3 (en) 2020-02-04 2025-10-07 Zhuhai Beihai Biotech Co Ltd Formulations of docetaxel
CN111529506B (zh) * 2020-05-18 2021-09-03 同济大学 一种两性霉素b白蛋白纳米制剂及其制备方法和应用
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
CN116744984A (zh) 2020-12-28 2023-09-12 达沃有限公司 包含蛋白质和多官能化改性的基于聚乙二醇的交联剂的反应性干粉状止血材料
KR102435211B1 (ko) * 2021-06-29 2022-08-23 (주)진셀바이오텍 알부민을 고효율로 생산하는 식물 세포주 및 이의 용도
CN114544926A (zh) * 2021-12-02 2022-05-27 浙江鑫科医疗科技有限公司 一种血清蛋白稳定剂
CN115236216B (zh) * 2022-06-07 2024-03-01 合肥和合医疗科技有限公司 高效液相色谱串联质谱检测全血中免疫抑制剂的试剂盒,其制备方法和检测方法
CN116212639A (zh) * 2023-02-28 2023-06-06 湖南科伦制药有限公司 一种去除药液中有机溶剂的方法及系统
CN116297963B (zh) * 2023-03-24 2024-12-27 四川汇宇制药股份有限公司 一种白蛋白结合型紫杉醇注射剂中辛酸钠含量的检测方法
CN120789284A (zh) * 2025-09-18 2025-10-17 通化安睿特生物制药股份有限公司 一种包载环孢菌素a的白蛋白结合型药物及制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4833013A (pt) * 1971-08-30 1973-05-07
DE2653534C2 (de) * 1975-12-22 1986-08-28 Baxter Travenol Laboratories, Inc., Deerfield, Ill. Feste Antihämophilen-Faktor-Präparation und Verfahren zu ihrer Herstellung
JPS58216126A (ja) * 1982-06-11 1983-12-15 Ono Pharmaceut Co Ltd 可容化製剤
DE3702105A1 (de) * 1987-01-24 1988-08-04 Bayer Ag Parenterale loesung
JPS63215640A (ja) * 1987-03-04 1988-09-08 Nippon Hai Potsukusu:Kk 易吸収性抗炎症剤及びその製造方法
WO1988006457A1 (fr) * 1987-03-04 1988-09-07 Nippon Hypox Laboratories Incorporated Composition medicinale contenant de l'albumine en tant que support et procede de preparation
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
US5356927A (en) * 1992-12-02 1994-10-18 Thomas Jefferson University Methods of treating plasmodium and babesia parasitic infections
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
GB9510716D0 (en) * 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
TR199600775A2 (tr) 1996-09-27 1997-09-21 Tureks Turunc Madencilik Ic Ve Taslara eskitilmis görüntü kazandirilmasi icin bir yöntem.
US5776912A (en) * 1996-12-20 1998-07-07 Schering Corporation Lipophilic oligosaccharide antibiotic compositions
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel

Also Published As

Publication number Publication date
TWI222365B (en) 2004-10-21
HRP980499A2 (en) 1999-12-31
US6743826B1 (en) 2004-06-01
NO20001371D0 (no) 2000-03-16
US20100076008A1 (en) 2010-03-25
SI20189B (sl) 2007-10-31
BG64749B1 (bg) 2006-02-28
ES2187062T3 (es) 2003-05-16
PT981375E (pt) 2003-04-30
PL339369A1 (en) 2000-12-18
US20050064028A1 (en) 2005-03-24
ATE230611T1 (de) 2003-01-15
WO1999013914A1 (en) 1999-03-25
HUP9701554D0 (en) 1997-11-28
JP2001508806A (ja) 2001-07-03
NZ503302A (en) 2001-08-31
EP0981375B1 (en) 2003-01-08
CZ2000952A3 (cs) 2000-09-13
LV12493A (en) 2000-06-20
BR9812469A (pt) 2002-02-05
LV12493B (en) 2001-01-20
NO20001371L (no) 2000-05-18
US7119124B2 (en) 2006-10-10
CN1189216C (zh) 2005-02-16
US7501455B2 (en) 2009-03-10
KR20010052072A (ko) 2001-06-25
AU734695B2 (en) 2001-06-21
IL135055A (en) 2004-09-27
BG104245A (en) 2000-11-30
US8946167B2 (en) 2015-02-03
TR200001545T2 (tr) 2000-10-23
DE69810612T2 (de) 2003-10-02
SI20189A (sl) 2000-10-31
LT2000018A (en) 2000-08-25
IL135055A0 (en) 2001-05-20
CZ301326B6 (cs) 2010-01-20
LT4736B (lt) 2000-12-27
RS50102B (sr) 2009-01-22
SK284683B6 (sk) 2005-09-08
DE69810612D1 (de) 2003-02-13
NO325294B1 (no) 2008-03-17
KR100587962B1 (ko) 2006-06-13
SK3292000A3 (en) 2000-08-14
CA2269923A1 (en) 1999-03-25
AU9362398A (en) 1999-04-05
US20040014655A1 (en) 2004-01-22
RO118695B1 (ro) 2003-09-30
AR017120A1 (es) 2001-08-22
PL193067B1 (pl) 2007-01-31
EA004700B1 (ru) 2004-06-24
US20070232536A1 (en) 2007-10-04
YU16600A (sh) 2003-08-29
CA2269923C (en) 2003-07-22
EP0981375A1 (en) 2000-03-01
ZA988585B (en) 2000-03-13
EA200000331A1 (ru) 2000-10-30
CN1270529A (zh) 2000-10-18

Similar Documents

Publication Publication Date Title
DK0981375T3 (da) Farmaceutiske præparater indeholdende plasmaprotein
DE69814091D1 (de) Voriconazol-enthaltende pharmazeutische zubereitungen
DE69831620D1 (de) Arzneizubereitungen enthaltend Kannabinoide
NO974618D0 (no) Farmasöytiske preparater for intranasal administrasjon
IS5953A (is) Lyfjablöndur úr örgerðum eplerenonum
ATE200027T1 (de) Tetrahydrolipstatin enthaltende präparate
FI974429L (fi) Suspendoituja peptidi/proteiinivalmisteita
PL336889A1 (en) Preparations of activated protein c
NO954146D0 (no) Belagte farmasöytiske preparater
DE69625368D1 (de) Schweisshemmende deodorierende präparaten
NO995712D0 (no) Oftalmiske preparater
NO983364L (no) Konsensusproteiner
ATE266383T1 (de) Dermatologische zubereitungen
NO980546D0 (no) Farmasöytiske midler
DK0988861T3 (da) Stabiliserede proteinpræparater
FI954986L (fi) Uudet, suun kautta annettavat, syklosporiinia sisältävät farmaseuttiset valmisteet
DK0925273T3 (da) Farmaceutiske præparater indeholdende 4-oxo-butansyrer
DE69926012D1 (de) Arzneizubereitungen
NO994619L (no) Farmasöytiske blandinger
ATE283706T1 (de) ßGEGEN RACEMISIERUNG STABILISIERTE PHARMAZEUTISCHE ZUBEREITUNGEN VON CILANSETRONß
EE9800275A (et) Misolastiini sisaldavad prolongeeritud toimega farmatseutilised preparaadid
DK1041966T3 (da) Farmaceutiske præparater omfattende zafirlukast
DE69906934D1 (de) Arzneizubereitungen
EP1142589A4 (en) Medicinal preparations
FI974610A0 (fi) Farmaceutiskt preparat i gelform